Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | PHASE1 | RECRUITING | 12 | — | — | Mar 18, 2026 | Sep 24, 2026 | Apr 15, 2026 | 3 | United States |
Number of participants with AEs as a measure of safety and tolerability
Number of participants with clinically significant changes in Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate, Electrocardiogram and hyposensitive events as a measure of adverse events
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Taken by mouth as capsules |
| HJB647 low dose | EXPERIMENTAL | Taken by mouth as capsule |
| HJB647 high dose | EXPERIMENTAL | Taken by mouth as capsule |
| Name | Type | Description |
|---|---|---|
| HJB647 low dose | DRUG | Study drug low dose in capsule form |
| HJB647 high dose | DRUG | Study drug high dose in capsule form |
| Placebo | OTHER | Placebo control in capsule form |
Inclusion Criteria: Participants eligible for inclusion in this study must meet all of the following criteria: * Men and women aged 18 years or older * Stable NYHA functional class II-III * LVEF \<50% * NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening * ...